BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenstrm’s Macroglobulinemia – Business…
BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the European Commission (EC) approved BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenstrms macroglobulinemia (WM) who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. The approval is applicable to all 27 European Union (EU) member states, plus Iceland and Norway. BeiGene is working to make this new treatment option available to WM patients in the EU as quickly as possible.
BTK inhibition is an established mode of treatment for patients with WM, and the approval of BRUKINSA provides an important new option for patients with WM that may offer improved outcomes, said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. Patients and their physicians in the EU will soon have access to an innovative medicine that has potential to offer deep and durable responses and improved tolerability, as seen in the ASPEN trial.
The EC approval for BRUKINSA follows a positive opinion granted in September by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), based on the results of the ASPEN trial. Although the primary endpoint of statistical superiority related to deep response, very good partial response (VGPR) or better, was not met, BRUKINSA demonstrated clinical benefit with advantages in safety compared to ibrutinib.1 Read more about the positive CHMP opinion and ASPEN trial results here.
With BRUKINSA now approved in the EU, we continue to execute on our commitment of making this potentially best-in-class BTK inhibitor available for more patients around the world who may benefit, said Jane Huang, M.D., Chief Medical Officer, Haematology at BeiGene. BRUKINSA was designed to maximize BTK occupancy and minimize off-target effects and has demonstrated efficacy and advantages in safety and tolerability over ibrutinib in the ASPEN trial. We believe BRUKINSA will become the preferred treatment option among patients with WM and their physicians.
We have built a strong team in Europe that is committed to creating access to BRUKINSA for patients living with WM, said Gerwin Winter, Senior Vice President, Head of Commercial, Europe at BeiGene. This approval by the European Commission is a significant milestone for BeiGenes expansion in the region, representing another step towards BeiGenes goal of increasing access to innovative oncology medicines globally.
About Waldenstrms Macroglobulinemia
Waldenstrms macroglobulinemia (WM) is a generally indolent and relatively rare B-cell malignancy characterized by bone marrow infiltration with monoclonal immunoglobulin M (IgM) secreting lymphoplasmacytic cells. WM represents approximately one percent of all non-Hodgkins lymphomas and typically progresses slowly after diagnosis.2 The disease usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved.3 Throughout Europe, the estimated incidence rate of WM is approximately seven out of every one million men and four out of every one million women.4
About the ASPEN trial
The Phase 3 randomized, open-label, multicentre ASPEN clinical trial (NCT03053440) evaluated BRUKINSA (zanubrutinib) versus ibrutinib in patients with relapsed or refractory (R/R) WM or treatment-nave (TN) WM considered unsuitable for treatment with chemoimmunotherapy. The primary objective was to establish superiority of BRUKINSA compared to ibrutinib as demonstrated by the proportion of patients achieving complete response or very good partial response. Secondary endpoints included major response rate (MRR), duration of response (DoR) and progression-free survival (PFS), and safety, measured by incidence, timing and severity of treatment-emergent adverse events. The pre-specified analysis populations for the trial included the overall population (n=201), of which the majority were R/R patients (n=164). Exploratory endpoints included quality of life measures.
As assessed by an independent review committee (IRC) based on the modified Sixth International Workshop on Waldenstrms Macroglobulinemia (IWWM-6) response criteria (Treon 2015), the combined rate of complete response (CR) and VGPR in the overall intention-to-treat (ITT) population was 28% with BRUKINSA (95% CI: 20, 38), compared to 19% with ibrutinib (95% CI: 12, 28). While this difference was not statistically significant, BRUKINSA did achieve numerically higher VGPR rates and trends towards increased response quality.1
In the ASPEN trial, BRUKINSA demonstrated a more favorable safety profile compared to ibrutinib with lower frequency of adverse reactions that have raised concern with BTK inhibitors, including atrial fibrillation or flutter (2% vs. 15%), minor bleeding (49% vs. 59%) and major hemorrhage (6% vs. 9%). Despite higher rates of grade 3 neutropenia, patients on BRUKINSA did not demonstrate higher rates of infection as compared to those receiving ibrutinib. Of the 101 patients with WM treated with BRUKINSA, 4% of patients discontinued due to adverse events, and adverse events leading to dose reduction occurred in 14% of patients.1
The study includes three arms in two cohorts, a randomized cohort (Cohort 1, N=201) consisting of patients with a MYD88 mutation (MYD88MUT) and a non-randomized cohort (Cohort 2, N=28) in which patients with MYD88 wild-type (MYD88WT) received BRUKINSA because historic data indicated they were unlikely to benefit from ibrutinib. The randomized Cohort 1 enrolled 102 patients (including 83 R/R patients and 19 TN patients) in the BRUKINSA arm and 99 patients (including 81 R/R patients and 18 TN patients) in the ibrutinib arm. Patients in the BRUKINSA arm were assigned to receive BRUKINSA 160 mg twice daily (BID) and patients in the ibrutinib arm received 420 mg of ibrutinib once daily (QD).
About BRUKINSA
BRUKINSA (zanubrutinib) is a small molecule inhibitor of Brutons tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease relevant tissues.
BRUKINSA is now approved in the United States, China, the European Union and nine other countries and regions. To date, more than 20 marketing authorization applications have been submitted for BRUKINSA for various indications.
Safety Information
The most commonly occurring adverse reactions (20%) were neutropenia (56.2%), thrombocytopenia (45.1%), upper respiratory tract infection (44.3%), hemorrhage/hematoma (32.2%), rash (29.8%), bruising (29.1%), anemia (28.9%), musculoskeletal pain (24.3%), diarrhea (23.6%), pneumonia (22.1%) and cough (21.7%).
The most common Grade 3 or higher adverse reactions (>5%) were neutropenia (28.0%), pneumonia (11.6%), thrombocytopenia (11.4%), and anemia (6.9%).
Of the 779 patients treated with zanubrutinib, 3.6% of patients discontinued treatment due to adverse reactions. The most frequent adverse reaction leading to treatment discontinuation was pneumonia (1.8%). Adverse reaction leading to dose reduction occurred in 4.9% of patients.
The recommended total daily dose of zanubrutinib is 320 mg. The daily dose may be taken either once daily (four 80 mg capsules) or divided into two doses of 160 mg twice daily (two 80 mg capsules).
BeiGene Oncology
BeiGene is committed to advancing best and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. We have a growing R&D team of approximately 2,750 colleagues dedicated to advancing more than 90 ongoing or planned clinical trials involving more than 14,000 patients and healthy volunteers. Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions. Haematology-oncology and solid tumour targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA in the United States, China, the EU, Canada, Australia, and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab as well as the PARP inhibitor pamiparib in China.
BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen and Bristol Myers Squibb. We also plan to address greater areas of unmet need globally through our collaborations including with Amgen, Bio-Thera, EUSA Pharma, Mirati Therapeutics, Seagen, and Zymeworks. BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. To learn more about BeiGene, please visit http://www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the planned commercialization and market access of BRUKINSA in the European Union and additional development, regulatory filings and potential approvals in other markets, the potential for BRUKINSA to be a best-in-class BTK inhibitor, the potential for BRUKINSA to provide improved clinical benefits with advantages in safety, the potential for BRUKINSA to become the preferred treatment option among patients with WM and their physicians, the potential commercial opportunity for BRUKINSA, and BeiGenes plans, commitments, aspirations and goals under the headings BeiGene Oncology and About BeiGene. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on the Companys clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
* BRUKINSA is approved in the following indications and regions:
a. This indication was approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
b. This indication was approved under conditional approval. Complete approval for this indication may be contingent upon results from ongoing randomized, controlled confirmatory clinical trials.
References:
1. Tam, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrm macroglobulinemia: the ASPEN study. Blood. October 2020. 136(18): 2038-2050.
2. Lymphoma Research Foundation. Getting the Facts: Waldenstrm Macroglobulinemia. Available at https://lymphoma.org/wp-content/uploads/2020/09/LRF-Waldenstrom-Macroglobulinemia_Factsheet.pdf. Updated 2020.
3. Lymphoma Research Foundation. Available at https://lymphoma.org/aboutlymphoma/nhl/wm/. Accessed December 2020.
4. Buske, C, et al. Treatment and outcome patterns in European patients with Waldenstrms macroglobulinaemia: a large, observational, retrospective chart review. The Lancet Haematology 2018; 5: e0299-309.
See the article here:
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenstrm's Macroglobulinemia - Business...
- Syria: Statement by the High Representative on behalf of the European Union on the fall of the Assad regime - consilium.europa.eu - December 10th, 2024 [December 10th, 2024]
- European Union and the Gates Foundation to co-host Gavi 6.0 High Level Pledging Summit - Bill & Melinda Gates Foundation - December 10th, 2024 [December 10th, 2024]
- European Union orders TikTok to preserve data related to Romanian election - The Associated Press - December 10th, 2024 [December 10th, 2024]
- European Union - United Republic of Tanzania: Joint Communique of the 2024 Partnership Dialogue - EEAS - December 10th, 2024 [December 10th, 2024]
- Human Rights Day: Statement by the High Representative on behalf of the European Union - consilium.europa.eu - December 10th, 2024 [December 10th, 2024]
- We are waiting to return home - helping refugees in Sudan - European Union - December 10th, 2024 [December 10th, 2024]
- Revised Regulation on Classification, Labelling and Packaging of Chemicals enters into force - European Union - December 10th, 2024 [December 10th, 2024]
- CCS legal framework for the development of carbon capture and storage technologies in Poland and the European Union - Dentons - December 10th, 2024 [December 10th, 2024]
- Mercosur and the European Union sign trade agreement - Fresh Fruit Portal - December 10th, 2024 [December 10th, 2024]
- European Union To Spend Over $4 Million And 3 Years To Create Report On European Animation Industry - Cartoon Brew - December 4th, 2024 [December 4th, 2024]
- Speech by President von der Leyen at the European Parliament Plenary on the new College of Commissioners and its programme - European Union - December 4th, 2024 [December 4th, 2024]
- ASSEMBLY | EU bishops reflect on Europes future and challenges of the new institutional cycle - The Catholic Church in the European Union - December 4th, 2024 [December 4th, 2024]
- Georgia suspends talks on joining the European Union and accuses the bloc of blackmail - The Associated Press - November 30th, 2024 [November 30th, 2024]
- An update on political advertising in the European Union - The Keyword - November 30th, 2024 [November 30th, 2024]
- Protesters met with force in Georgia following suspension of talks on European Union accession - Civil Rights Defenders - November 30th, 2024 [November 30th, 2024]
- European Union Food Week is Coming to Hyundai Food Market - EEAS - November 30th, 2024 [November 30th, 2024]
- The European Union and International IDEA organised a study visit to Kenya for the National Assembly Gender Committee and the CSO Gender Platform -... - November 30th, 2024 [November 30th, 2024]
- Malawi and the European Union hold Partnership Dialogue - EEAS - November 30th, 2024 [November 30th, 2024]
- Georgia suspends talks on joining the European Union and accuses the bloc of blackmail - News-Press Now - November 30th, 2024 [November 30th, 2024]
- If you're traveling outside the United States this Christmas, you'll have to meet a new requirement to enter the European Union - it's now official -... - November 14th, 2024 [November 14th, 2024]
- What the European Union should expect from Trumps tariffs - Bruegel - November 14th, 2024 [November 14th, 2024]
- Ten countries hope to join the European Union. Here is their formal status - Reuters - November 5th, 2024 [November 5th, 2024]
- What Does an European Union Investigation Mean for Temu? - The Fashion Law - November 5th, 2024 [November 5th, 2024]
- Joint Statement by the European Commission and High Representative Josep Borrell on the second round of Presidential Elections in Moldova - European... - November 5th, 2024 [November 5th, 2024]
- Spanish fugitive deported to European Union country: NIA - Focus Taiwan - October 21st, 2024 [October 21st, 2024]
- Trump says Tim Cook called him to complain about the European Union - The Verge - October 21st, 2024 [October 21st, 2024]
- Joint Press Release : First Partnership Dialogue between the Republic of Seychelles and the European Union - EEAS - October 21st, 2024 [October 21st, 2024]
- European Union member States must shield the International Criminal Court from critical threats - FIDH - October 21st, 2024 [October 21st, 2024]
- Can the European Union get it together on capital markets? This is whats at stake - World Economic Forum - October 21st, 2024 [October 21st, 2024]
- Migration And Asylum Offshoring Top Of European Union Council Agenda - Forbes - October 21st, 2024 [October 21st, 2024]
- Intrigue is unfolding in Moldova around the referendum on joining the European Union - Eurasia Daily - October 21st, 2024 [October 21st, 2024]
- The European Union as a strong actor at the 57th session of the Human Rights Council - EEAS - October 21st, 2024 [October 21st, 2024]
- Meta to European Union: Your Tech Rules Threaten to Squelch the AI Boom - The Wall Street Journal - September 19th, 2024 [September 19th, 2024]
- European Union Considers Suspending Visa Free Travel for Georgia After October 16 Elections Amid Political Tensions and Strained Relations - Travel... - September 19th, 2024 [September 19th, 2024]
- Teva faces European Union antitrust fine over shenanigans to thwart rivals - The Times of Israel - September 12th, 2024 [September 12th, 2024]
- Auditors say European Union is likely exaggerating green spending - The Hindu - September 12th, 2024 [September 12th, 2024]
- China's Wang Wentao to discuss the high European Union tariffs on electric cars next week - HT Auto - September 12th, 2024 [September 12th, 2024]
- Travel Update- Schengen Travelers To Experience A New Era As European Union will begin automated stamping for passports - Travel And Tour World - August 25th, 2024 [August 25th, 2024]
- The Largest Standing Armies of the European Union - Worldatlas.com - August 25th, 2024 [August 25th, 2024]
- China questions, begins probe of European Union subsidies for dairy industry exports - Voice of America - VOA News - August 25th, 2024 [August 25th, 2024]
- Von der Leyen, Costa and Kallas have been approved for EU top jobs. Who are they? What do they do? - KELOLAND.com - June 27th, 2024 [June 27th, 2024]
- Von der Leyen, Costa and Kallas have been approved for EU top jobs. Who are they? What do they do? - WRIC ABC 8News - June 27th, 2024 [June 27th, 2024]
- Apple Intelligence Features Not Coming to European Union at Launch Due to DMA - MacRumors - June 27th, 2024 [June 27th, 2024]
- European Union leaders set to endorse Von der Leyen, Costa and Kallas for the bloc's top jobs | Daily Independent - Daily Independent - June 27th, 2024 [June 27th, 2024]
- European Union leaders agree on top officials who will be the face of world's largest trading bloc - Citrus County Chronicle - June 27th, 2024 [June 27th, 2024]
- Not All Tariffs Are the Same: The Core Differences between U.S. and EU Tariffs against Chinese EVs - CSIS | Center for Strategic and International... - June 27th, 2024 [June 27th, 2024]
- Seeking Safety in Cyprus, They're Stuck in Island's U.N. Buffer Zone - The New York Times - June 12th, 2024 [June 12th, 2024]
- What to Know About Europe's Extra Tariffs on Chinese Electric Cars - The New York Times - June 12th, 2024 [June 12th, 2024]
- The EU slaps additional tariffs on Chinese EV imports - The Verge - June 12th, 2024 [June 12th, 2024]
- Battered by Far Right in E.U. Vote, Macron Calls for New Elections in France - The New York Times - June 12th, 2024 [June 12th, 2024]
- Chinese EV makers face additional tariffs of up to 38 percent in the EU - Engadget - June 12th, 2024 [June 12th, 2024]
- Poland exit polls: PM Tusk keeps upper hand over PiS in EU elections - Euronews - June 12th, 2024 [June 12th, 2024]
- The European Union mobilises additional assistance to support Ukraine - European Union - June 12th, 2024 [June 12th, 2024]
- Far-right parties make stunning gains in EU election, prompting Macron to call snap vote in France - Fortune - June 12th, 2024 [June 12th, 2024]
- EU's Borrell: Rafah offensive will cause civilian casualties, no matter what Israel says - The Times of Israel - May 7th, 2024 [May 7th, 2024]
- Who would run the EU if decided by Eurovision? - POLITICO Europe - May 7th, 2024 [May 7th, 2024]
- Opinion | Europe Is About to Drown in the River of the Radical Right - The New York Times - May 7th, 2024 [May 7th, 2024]
- Poland's Tusk Calls on EU to Build Joint Air-Defense System - Yahoo! Voices - May 7th, 2024 [May 7th, 2024]
- Xi visits Europe amid growing tensions with the West - Courthouse News Service - May 7th, 2024 [May 7th, 2024]
- Netherlands joins call to shetler intercepted asylum seekers in non-EU countries: report - NL Times - May 7th, 2024 [May 7th, 2024]
- More civilians will be killed in Israel's Rafah offensive 'whatever they say' - EU's Borrell - The Jerusalem Post - May 7th, 2024 [May 7th, 2024]
- Lawyer: EU taxpayers might have to pay billions for Russian billionaire's unjustified inclusion on a sanctions list - bnn-news.com - May 7th, 2024 [May 7th, 2024]
- EU urged to have fair perception of China - China Daily - May 7th, 2024 [May 7th, 2024]
- EU hosts defence forum to rally its military industry behind Ukraine - Euronews - May 7th, 2024 [May 7th, 2024]
- EU in Tug-of-War for Georgia and Moldova - Center for European Policy Analysis - May 7th, 2024 [May 7th, 2024]
- EU Commission ends rule of law proceedings against Poland after six years - JURIST - May 7th, 2024 [May 7th, 2024]
- Seven out of 10 Europeans believe their country takes in too many immigrants - EL PAS USA - May 7th, 2024 [May 7th, 2024]
- George Robertson: Why Russia fears the European Union - The New Statesman - May 3rd, 2024 [May 3rd, 2024]
- Meta Faces EU Investigation Over Election Disinformation - The New York Times - May 3rd, 2024 [May 3rd, 2024]
- Europeans lack visceral attachment to the EU. Does it matter? - The Economist - May 3rd, 2024 [May 3rd, 2024]
- Europe's East Will Soon Overtake Club Med for Living Standards - Yahoo! Voices - May 3rd, 2024 [May 3rd, 2024]
- German Foreign Minister Aims To Abolish Veto in EU Council Ahead of Enlargement - The European Conservative - May 3rd, 2024 [May 3rd, 2024]
- Le Pen urges 'crushing' defeat of Macron in speech ahead of European elections - Le Monde - May 3rd, 2024 [May 3rd, 2024]
- The European Union is investigating Meta's election policies - Engadget - May 3rd, 2024 [May 3rd, 2024]
- Activists press for EU-wide abortion right - POLITICO Europe - May 3rd, 2024 [May 3rd, 2024]
- In the upcoming European elections, peace and security matter the most - Euronews - May 3rd, 2024 [May 3rd, 2024]
- The Greens' Reintke vows to keep EU on track towards climate neutrality amid right-wing backlash - Euronews - May 3rd, 2024 [May 3rd, 2024]
- President von der Leyen reaffirms EU's strong support for Lebanon and its people and announces a 1 billion package ... - European Union - May 3rd, 2024 [May 3rd, 2024]
- GDP up by 0.3% in both the euro area and the EU - European Commission - May 3rd, 2024 [May 3rd, 2024]
- Possible to enlarge and deepen EU at the same time, Barroso says - EURACTIV - May 3rd, 2024 [May 3rd, 2024]